Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849674 | 0.71 | — | — | |
| SCHEMBL22779169 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL22797358 | 0.71 | DPP4 (0.44) | — | |
| SCHEMBL7580960 | 0.67 | CYP2C19 (0.39) | CES2CES1 | |
| SCHEMBL8305778 | 0.67 | APP (0.50) | — | |
| SCHEMBL21189785 | 0.67 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL29216895 | 0.65 | IKBKB (0.36) | — | |
| SCHEMBL12964481 | 0.65 | SNCA (0.38) | CES2CES1 | |
| SCHEMBL21952065 | 0.64 | MAPK10 (0.31) | — | |
| SCHEMBL22163273 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-04-27 | — | — | US | disclosed |
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS2, LGALS3 | CES2 2520/4885CES1 804/4885 |
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS2, LGALS3 | CES2 2520/4885CES1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.